Serum Outperforms Plasma for Glypican-3 Quantification in Hepatocellular Carcinoma—A Prospective Comparative Study

<b>Background:</b> Glypican-3 (GPC3) is frequently overexpressed in hepatocellular carcinoma (HCC) and serves as a circulating biomarker. Limited evidence exists regarding whether plasma or serum constitutes the optimal matrix for GPC3 measurement. This study aimed to investigate this gap. <b>Methods:</b> Between December 2024 and September 2025, 100 participants were prospectively enrolled, including 33 healthy controls, 29 individuals with chronic liver disease, and 38 patients with HCC. Paired serum and plasma samples were analyzed under fresh conditions and after storage for seven days at 4 °C and -70 °C. GPC3 concentrations were compared across groups. Subsequently, correlation and area under the receiver operating characteristic curve (AUROC) analyses were conducted. <b>Results:</b> In fresh samples of the controls, median plasma GPC3 levels were significantly higher than those in serum (82.36 pg/mL, IQR: 67.56-92.42 vs. 30.89 pg/mL, IQR: 20.36-41.12; <i>p</i> < 0.001). After seven days of storage, plasma GPC3 concentrations declined markedly at both 4 °C (41.73 pg/mL, IQR: 32.49-55.37; <i>p</i> < 0.001) and -70 °C (45.53 pg/mL, IQR: 25.30-55.65; <i>p</i> < 0.001), with no significant difference between the two storage conditions (<i>p</i> = 0.610). In contrast, serum GPC3 levels remained relatively stable across fresh, 4 °C (31.10 pg/mL, IQR: 16.84-38.60), and -70 °C (25.31 pg/mL, IQR: 14.36-40.74) conditions (<i>p</i> = 0.645). Both matrices under -70 °C storage effectively discriminated HCC from non-HCC cases, although serum demonstrated a significantly better diagnostic performance (AUROC: 0.836, 95% CI: 0.749-0.902 vs. 0.772, 95% CI: 0.677-0.850; <i>p</i> = 0.013). <b>Conclusions:</b> Although plasma offers operational convenience and higher baseline GPC3 levels, serum provides both greater stability and superior diagnostic accuracy under frozen conditions, thus supporting its use as the preferred specimen matrix in clinical and research applications.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-01-07
DOI
https://doi.org/10.3390/jcm15020448
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Serum Outperforms Plasma for Glypican-3 Quantification in Hepatocellular Carcinoma—A Prospective Comparative Study

Chen-Shiou Wu, Hsin‐Ju Tsai, Jiunn-Min Wang, Hui-Fen Liu et al.
Journal of Clinical Medicine
Hepatocellular Carcinoma Treatment and Prognosis
article

Serum Outperforms Plasma for Glypican-3 Quantification in Hepatocellular Carcinoma—A Prospective Comparative Study

Chen-Shiou Wu, Hsin‐Ju Tsai, Jiunn-Min Wang, Hui-Fen Liu, Teng-Yu Lee, Shou-Wu Lee, Chia-Chang Chen, Ming-Tze Yang, Ying-Cheng Lin
article en

Abstract

<b>Background:</b> Glypican-3 (GPC3) is frequently overexpressed in hepatocellular carcinoma (HCC) and serves as a circulating biomarker. Limited evidence exists regarding whether plasma or serum constitutes the optimal matrix for GPC3 measurement. This study aimed to investigate this gap. <b>Methods:</b> Between December 2024 and September 2025, 100 participants were prospectively enrolled, including 33 healthy controls, 29 individuals with chronic liver disease, and 38 patients with HCC. Paired serum and plasma samples were analyzed under fresh conditions and after storage for seven days at 4 °C and -70 °C. GPC3 concentrations were compared across groups. Subsequently, correlation and area under the receiver operating characteristic curve (AUROC) analyses were conducted. <b>Results:</b> In fresh samples of the controls, median plasma GPC3 levels were significantly higher than those in serum (82.36 pg/mL, IQR: 67.56-92.42 vs. 30.89 pg/mL, IQR: 20.36-41.12; <i>p</i> < 0.001). After seven days of storage, plasma GPC3 concentrations declined markedly at both 4 °C (41.73 pg/mL, IQR: 32.49-55.37; <i>p</i> < 0.001) and -70 °C (45.53 pg/mL, IQR: 25.30-55.65; <i>p</i> < 0.001), with no significant difference between the two storage conditions (<i>p</i> = 0.610). In contrast, serum GPC3 levels remained relatively stable across fresh, 4 °C (31.10 pg/mL, IQR: 16.84-38.60), and -70 °C (25.31 pg/mL, IQR: 14.36-40.74) conditions (<i>p</i> = 0.645). Both matrices under -70 °C storage effectively discriminated HCC from non-HCC cases, although serum demonstrated a significantly better diagnostic performance (AUROC: 0.836, 95% CI: 0.749-0.902 vs. 0.772, 95% CI: 0.677-0.850; <i>p</i> = 0.013). <b>Conclusions:</b> Although plasma offers operational convenience and higher baseline GPC3 levels, serum provides both greater stability and superior diagnostic accuracy under frozen conditions, thus supporting its use as the preferred specimen matrix in clinical and research applications.

Journal of Clinical MedicineVol. 15(2)
National Chung Hsing University (TW), Taichung Veterans General Hospital (TW), Taipei Tzu Chi Hospital (TW), Chung Shan Medical University (TW)
Taichung Veterans General Hospital, National Science and Technology Council
Reduced inequalities
Openalex Percentile: Top 98%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.